Hengrui Pharma Repurchases 442,600 A Shares for RMB 20.00 Million Under ESOP

Bulletin Express10-13

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (Hengrui Pharma; HKEX: 01276, SSE: 600276) has disclosed the repurchase of 442,600 A shares on 13 October 2026 via the Shanghai Stock Exchange, according to its Next Day Disclosure Return filed with the Hong Kong Stock Exchange on 13 October 2026.

The shares were bought back at prices ranging from RMB 44.80 to RMB 45.55, delivering a volume-weighted average cost of RMB 45.19 per share and a total outlay of approximately RMB 19.999 million. The repurchased shares, designated for the company’s A Share Employee Stock Ownership Schemes, will be held as treasury shares; no cancellation has been announced.

Post-transaction, Hengrui Pharma’s issued share capital (excluding treasury shares) fell by 0.007 % to 6.36654 billion shares, while treasury shares rose to 12.46 million. The total number of issued shares remained unchanged at 6.37900 billion.

The company’s board confirmed that the repurchase was duly authorised and executed in full compliance with applicable listing rules and regulatory requirements. The disclosure was signed by Executive Director, General Manager (President) and Chief Operating Officer Mr Feng Ji on behalf of the company.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment